Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Zaspopathy in a large classic late-onset distal myopathy family.

Authors: Griggs, R  Vihola, A  Hackman, P  Talvinen, K  Haravuori, H  Faulkner, G  Eymard, B  Richard, I  Selcen, D  Engel, A  Carpen, O  Udd, B 
Citation: Griggs R, etal., Brain. 2007 Jun;130(Pt 6):1477-84. Epub 2007 Mar 2.
Pubmed: (View Article at PubMed) PMID:17337483
DOI: Full-text: DOI:10.1093/brain/awm006

Distal myopathies have been associated with mutations in titin, dysferlin, GNE, desmin and myosin. Of these, only titin mutations were previously known to cause dominant late-onset distal myopathy. Recent findings, however, have indicated that patients affected with myofibrillar myopathy have a more distal than proximal muscle phenotype and a proportion of these may have mutations in myotilin, ZASP or filamin C, besides previously known desmin and alphaB-crystallin. Here we report that the disorder in one of the well-characterized autosomal dominant distal myopathy families, the Markesbery et al. family, first reported in 1974, is caused by ZASP mutation A165V. Previous linkage to the titin locus 2q31 proved incorrect. ZASP expression by immunoblotting shows normal presence of the main 32 and 78 kDa bands and immunohistochemistry in patients reveals normal Z-disc localization except for moderate accumulations together with myotilin, desmin alphaB-crystallin and alpha-actinin. Muscle imaging reveals involvement in both the posterior and anterior compartments of the lower leg and considerable affection of proximal leg muscles at later stages. Haplotype studies in this family and in five other unrelated families with European ancestry carrying the identical A165V mutation share common markers at the locus suggesting the existence of a founder mutation.


Disease Annotations
Objects Annotated

Additional Information

CRRD Object Information
CRRD ID: 11068981
Created: 2016-04-27
Species: All species
Last Modified: 2016-04-27
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.